About BIQSFP
As part of its Prioritization and Scientific Quality Initiatives, the NCI Clinical Trials Working Group (CTWG) recommended establishing a funding mechanism and prioritization process for correlative studies and quality of life studies that are incorporated into the fundamental design of a clinical trial and are not currently supported by the U10 funding mechanism. The purpose of the BIQSFP is to ensure that the most important, scientifically meritorious biomarker, imaging, and quality of life studies or CEA can be initiated in a timely manner in association with appropriate clinical trials.
Targeted biological studies, imaging, and quality of life studies embedded in clinical trials should have the potential to modify standard of practice. The tests/assays must be reliable and provide interpretable answers that are of benefit to patients leading to scientific observations that validate targets, reduce morbidity, predict treatment effectiveness, facilitate better clinical trial design, identify populations that may better benefit from treatment, and improve clinical trial accrual and retention.
In 2010, the NCI Clinical Trials and Translational Research Advisory Committee (CTAC) recommended the addition of Cost-Effectiveness Analysis (CEA) to the BIQSFP (View Cost-Effectiveness Analysis Working Group Report). The purpose of CEA is to ensure that the most important cost-effectiveness analyses can be conducted in association with appropriate NCI-sponsored clinical trials.
Download Complete 2012 Announcement
(View 2011 Announcement)
(View 2010 Announcement)
